2 recruiting, 1 not yet recruiting. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow IrAE: new trials by email Literature Review of IrAE trials Research Report on IrAE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer Vedolizumab, Placebo - IrAE, Immune-related Adverse Event | Phase 2 / Phase 3 | Recruiting | AHS Cancer Control Alberta | 36 | 2026-08-13 | 2026-08-27 |
| The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities ondansetron - Hepatocellular Carcinoma (HCC), IrAE | Phase 2 | Recruiting | First Affiliated Hospital of Wenzhou Medical University | 134 | 2026-04-30 | 2026-08-04 |
| Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer golidocitinib - IrAE, Hematologic Disorder | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Guangzhou Medical University | 16 | 2026-02-01 | 2025-12-26 |
Carcinoma, Hepatocellular (1) · Colitis (1) · Diarrhea (1) · Hematologic Diseases (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1)
Digestive System Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Pathological Conditions, Signs and Symptoms (2) · Adenocarcinoma (1) · Carcinoma (1) · Colonic Diseases (1) · Digestive System Neoplasms (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1) · Hemic and Lymphatic Diseases (1) · Intestinal Diseases (1) · Liver Diseases (1) · Liver Neoplasms (1) · Lung Diseases (1)
Ondansetron (1) · vedolizumab (1)
AHS Cancer Control Alberta (1) · First Affiliated Hospital of Wenzhou Medical University (1) · The First Affiliated Hospital of Guangzhou Medical University (1)
China (2) · Canada (1)